ClinicalTrials.gov
public full text
Public Domain
LEO 32731 - A Phase I Study in Healthy Subjects
LEO 32731 ("Study Drug") is an investigational drug which is being developed by LEO Pharma A/S ("the Sponsor") for treatment of psoriasis. The aim (s) of this Study are to determine: * The safety and tolerability of the Study Drug and any side effects that might be associated with it * The Study will also measure how much of the Study Drug that gets into the blood and how long time it takes for the body to remove it.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Study to Look at the Safety of NNC0363-0845 in Healthy People and People With Type 1 Diabetes#866173
- Assessing the PK of Met DR, Met IR, and Met XR in Healthy Subjects#158170
- Omarigliptin & Trelagliptin in Twelve Healthy Egyptian Volunteers#831026
- A Study of Evacetrapib (LY2484595) in Participants With Severe Renal Impairment and in Healthy Participants#800317
- An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance to Monitor the Safety and/or Efficacy of AVANDAMET Between June 2004 and January 2010#848691
Record · ID 832422
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive